Aclaris Therapeutics: Future Prospects in Immunoinflammatory Diseases - Guggenheim Recommends Buy with a Potential of 159%!
Reading Time: 3 minutes
Strategic Direction and Core Competencies Aclaris Therapeutics (ACRS) is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immunologically driven inflammatory diseases. From the corporate perspective, the core mission is to translate complex scientific discoveries into practical and highly effective therapies for patients. These patients, suffering from severe skin and respiratory diseases, represent the end users of future solutions. The company employs a dual and innovative approach that includes both...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
